drugset / Trial / NCT01376349
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms
Phase 3
Completed
464 enrolled
Alliance for Clinical Trials in Oncology
Mayo Clinic · collabNational Cancer Institute (NCI) · collab
RandomizedParallel-groupDouble-blindSupportive care
Summary
RATIONALE: Dehydroepiandrosterone (DHEA) may help relieve vaginal symptoms in female cancer survivors. PURPOSE: This randomized phase III trial studies DHEA to see how well it works compared to placebo in treating postmenopausal cancer survivors with vaginal symptoms.
Timeline
- Start
- 2011-07
- Primary completion
- 2013-08
- Completion
- 2017-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dehydroepiandrosterone | Other / unclassified | 3.25 mg | Other |
| Subject | Dehydroepiandrosterone | Other / unclassified | 6.5 mg | Other |